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Abstract 
Objective  To evaluate immediate transcatheter aortic valve implantation (TAVI) results and medium-term follow-up in very elderly pa-
tients with severe and symptomatic aortic stenosis (AS). Methods  This multicenter, observational and prospective study was carried out in three 
hospitals. We included consecutive very elderly (> 85 years) patients with severe AS treated by TAVI. The primary endpoint was to evaluate 
death rates from any cause at two years. Results  The study included 160 consecutive patients with a mean age of 87 ± 2.1 years (range from 85 
to 94 years) and a mean logistic EuroSCORE of 18.8% ± 11.2% with 57 (35.6%) patients scoring ≥ 20%. Procedural success rate was 97.5%, 
with 25 (15.6%) patients experiencing acute complications with major bleeding (the most frequent). Global mortality rate during hospitalization 
was 8.8% (n = 14) and 30-day mortality rate was 10% (n = 16). Median follow up period was 252.24 ± 232.17 days. During the follow-up period, 
28 (17.5%) patients died (17 of them due to cardiac causes). The estimated two year overall and cardiac survival rates using the Kaplan-Meier 
method were 71% and 86.4%, respectively. Cox proportional hazard regression showed that the variable EuroSCORE ≥ 20 was the unique vari-
able associated with overall mortality. Conclusions  TAVI is safe and effective in a selected population of very elderly patients. Our findings 
support the adoption of this new procedure in this complex group of patients.  
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1  Introduction  
Aortic stenosis (AS) is the most frequent cardiac valve 
disease worldwide and the most common etiology is a de-
generative cause. According to the increment of life expec-
tancy, the prevalence of degenerative AS is increasing with 
the ageing of the population.[1,2] 
In recent years, transcatheter aortic valve implantation 
(TAVI) has become an effective and safe alternative treat-
ment for AS in patients with high pre-operative risk, or con-
traindication for surgery.[3,4] 
Usual pre-operative risk evaluation scales, such as Eu-
roSCORE and STS, evaluate concomitant pathologies that 
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may increase morbidity and mortality rates. Ageing is one 
of the major factors emerging from these scales of evalua-
tion.[5−10] 
It is well known that ageing and quality of life may co-
exist, so one of the most relevant factors for keeping this 
relationship is the autonomy of the patient.[11] 
In many very elderly patients, symptoms induced by se-
vere AS are the only limitative factors worsening their qual-
ity of life. Nonetheless, they are usually rejected for surgical 
treatment because of the prohibitive pre-operative risk asso-
ciated with age.[7,10] 
In relation to studies that have evaluated the efficacy of 
TAVI, and although elderly patients have been included, no 
one has been especially designed to address the evolution 
and outcomes in this concerned group of very elderly pa-
tients. The aim of our study is to evaluate immediate TAVI 
results and medium-term follow-up in very elderly patients 
with severe and symptomatic AS. 
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2  Methods 
2.1  Study population 
This is a multicenter, prospective and observational study. 
From December 2007 to April 2012, a total of 160 consecu-
tive patients recruited from 449 patients treated at three high 
volume hospitals were included in the study. The patients 
either suffered severe and symptomatic AS, which posed 
high surgical risk or an inoperable condition (n = 117), or 
rejected surgical intervention (n = 43). Each patient was 
evaluated by a multidisciplinary “Heart Team” (clinical 
cardiologists, cardiac interventionists, and surgeons).[4,12] 
Inclusion criteria were: ≥ 85 year old patients with severe 
and symptomatic AS with an affecting area less than 1 cm2 
(Indexed area < 0.6 cm2/m2); a diameter of the aortic annu-
lus measured by transesophageal echocardiogram between 
18 mm and 29 mm, and an ascending aorta diameter 40 mm 
above the aortic annulus ≤ 40 (26 mm prosthesis), or ≤ 43 
(29 and 31 mm prosthesis). 
Exclusion criteria included (n = 8): hypersensitivity or 
contraindication to the administration of any of the medica-
tions needed during the procedure; myocardial infarction 
during the 30 days prior to the procedure; presence of 
thrombi in left cavities; ejection fraction < 20%; recent 
stroke (three months after implantation); sepsis or endocar-
ditis; aneurisms of the aorta; coagulopathy or haemorrhagic 
diathesis; and severe mitral regurgitation.  
Prior to the procedure, coronary, aortic and iliofemoral 
angiography, transthoracic and transesophageal echocardio-
gram (if transthoracic examination proved inconclusive), 
and in some cases contrast CT was performed. The logistic 
EuroSCORE validated scale was used to evaluate pre-op-
erative risk.[5] 
Follow-up was obtained on all patients through personal 
interview at the cardiology office. Written and signed in-
formed consent was obtained in all cases. 
2.2  Description of the device 
The device (CoreValveReValving System®) consists of 
three elements: (1) triple-leaflet aortic prosthesis made of 
porcine pericardium, which is fitted on top of a self ex-
panding nitinol stent—there are four valve sizes (23, 26, 29 
and 31 mm) for aortic annuli ranging from 18 to 29 mm in 
diameter; (2) 18 F releasing catheter; and (3) loading sys-
tem. 
2.3  TAVI procedure 
Technical aspects of TAVI procedure have been previ-
ously described in detail.[13−15] Implantation was carried out 
in the cardiac catheterization laboratory under general anes-
thesia and deep sedation, or local anesthesia as deemed 
suitable by the anesthesiologist. All patients received pro-
phylactic antibiotic therapy with cephalosporins, except 
those allergic to β-lactams, who received vancomycin. 
Vascular access was femoral, the procedure being entirely 
percutaneous in the vast majority of cases and in a minority 
subclavian/axillar (five cases), which involved open surgery 
(in cases of excessive calcification, twisted arteries or 
atherosclerosis of the iliofemoral region, or when the di-
ameter of the iliac/femoral arteries was < 6 mm). When the 
procedure was performed by the transfemoral approach, it 
was completed by percutaneous closure of both femoral 
arteries; the femoral artery through which the device was 
implanted was closed using a previously implanted 
PROSTAR XL® device and the contralateral femoral artery 
was closed using PERCLOSE® or ANGIOSEAL®. When 
access was subclavian, the artery was surgically exposed 
and then punctured using the Seldinger technique, and the 
procedure was identical to that used for femoral access. Fi-
nally, the artery was surgically closed. The details of the 
hospital management of the patients have been previously 
described.[13−15] 
2.4  Primary endpoint 
The main endpoint of this study was to evaluate death 
rates from any cause at two years. 
2.5  Definitions 
The following definitions are referred to co-morbidities, 
complications and end points and were defined according to 
the Valve Academic Research Consortium (VARC): device 
success, cardiovascular death, renal failure, peri-procedural 
and spontaneous myocardial infarction, strokes, bleeding, 
combined safety and efficacy endpoints and echocardio-
graphic criteria post-implantation.[16] Acute myocardial in-
farction (AMI) was defined according to current European 
Guidelines.[17−19] 
2.6  Statistical analysis 
The Kolmogorov-Smirnov test was used to verify the 
normality of the distribution of the variables. The data are 
expressed as the mean ± SD for continuous variables and as 
numbers and percentages for categorical variables. A basic 
descriptive analysis and Kaplan-Meier survival analysis 
were performed. Cox proportional hazard regression was 
performed to identify the main covariates associated to 
mortality. Statistical analysis was performed using the SPSS 
version 19 program (Chicago, Illinois, USA). 
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3  Results 
3.1  Population 
Baseline characteristics of the population are shown in 
Table 1. From December 2007 to April 2012, 160 consecu-
tive patients (54 men, 33.8%; average age, 87 ± 2.1 years; 
range, 85−94 years) were included in the study. Sixteen 
(10%) patients were ≥ 90 year old. Peak and mean systolic 
gradients of 86.3 ± 23.3 mmHg and 52.6 ± 15.2 mmHg, 
respectively. The average aortic valve area was 0.63 ± 0.18 
cm2. NYHA functional classes III or IV were present in 124 
patients (77.5%) and 29 patients (18.1%) had impaired left 
ventricular 
Table 1.  Characteristics of the population (n = 160). 
Age years (range) 87 ± 2 (85-94) 
Males 54 (33.8) 
BMI, kg/m2 27.21 ± 4.61 
Logistic EuroSCORE  18.85% ± 11.21% 
Logistic EuroSCORE > 20%, 
NYHA functional class 
57 (35.6) 
    Class I 
   Class II 
   Class III 
   Class IV 
1 (0.6) 
35 (21.9) 
103 (64.4) 
21 (13.1) 
Angina 
Syncope, 
Chronic Renal Failure 
Porcelain aorta 
LVEF < 50% 
Previous biological valvular replacement 
Patients who reject surgical treatment 
53 (33.1) 
19 (11.9) 
36 (22.5) 
11 (6.9) 
29 (18.1) 
3 (1.9) 
43 (24.4) 
Cardiovascular risk factors  
Diabetes Mellitus 32 (20) 
Dyslipidemia 58 (36.3) 
Hypertension 118 (73.8) 
Cardiovascular history  
Extra cardiac vascular disease 16 (10) 
Previous AMI 10 (6.3) 
Previous stroke 12 (7.5) 
Pacemaker  16 (10) 
Coronary disease 62 (38.8) 
Previous coronary revascularization  28 (17.5) 
PCI before TAVI 16 (10) 
Echocardiographic parameters  
Maximum gradient, mmHg 86.33 ± 23.34 
Medium gradient, mmHg 52.64 ± 15.24 
Aortic valve area, cm2 0.63 ± 0.18 
Aortic annulus, mm 22.41 ± 1.96 
LVEF 61.48% ± 12.79% 
Data are presented as mean ± SD or n (%) unless other indicated. AMI: 
acute myocardial infarction; BMI: body mass index; EuroSCORE: European 
System for Cardiac Operative Risk Evaluation; LVEF: Left ventricular ejec-
tion fraction; NYHA: New York Heart Association; PCI: percutaneous coro-
nary intervention; TAVI: transcatheter aortic valve implantation. 
ejection fraction. The average logistic EuroSCORE was 
18.8% ± 11.2% (range 7%−81.3%), with 57 (35.6%) pa-
tients scoring ≥ 20%. 
3.2  Procedure data  
Procedural characteristics are shown in Table 2. General 
anesthesia was used in 45 patients. Transfemoral approach 
was mainly used (96.8%). Procedural success was achieved 
in 97.5% of the cases without surgery conversion. Acute 
complications were present in 25 (15.6%) patients, with 
major bleeding the most frequent (10 cases). 
Table 2.  Procedure data and acute complications (n = 160). 
General anesthesia 
Femoral approach 
45 (28.1) 
155 (96.8) 
Subclavian/axillar approach 5 (3.2) 
Prosthesis size 
26 mm 77 (48.1) 
29 mm 
31 mm 
78 (48.8) 
4 (2.5) 
   Not implanted 1 (0.6) 
Prosthesis post-dilatation 30 (18.8) 
Residual aortic regurgitation 
   Grade < 1 114 (71.3) 
   Grade 2 46 (28.7) 
Peak to peak post-procedural gradient. mmHg 3.93 ± 8.08 
Procedure time, min 106.41 ± 46.94 
Malposition 2 (1.3) 
Second prosthesis implanted 2 (1.3) 
Conversion to surgery 0 (0%) 
Procedural success 156 (97.5) 
Acute complications 25 (15.63) 
Cardiac tamponade 1 (0.6) 
Ring rupture/aortic dissection 1 (0.6) 
Procedural-relatedmyocardial infarction 4 (2.5) 
Mayor bleeding 10 (6.3) 
Mayor vascular complications 9 (5.6)  
Data are presented as mean ± SD or n (%). 
 
3.3  Outcomes and follow-up 
Follow up data are shown in Table 3. Mean length of 
hospital stay was 10.42 days. All patients were discharged 
to home. Global mortality rate during hospitalization was 
8.8% (n = 14) and 30-day mortality rate was 10% (n = 16). 
The NYHA functional class distribution one month after 
TAVI implantation was: NYHA I, 33 patients (20.6%); 
NYHA II, 89 patients (55.6%); NYHA III, 34 patients 
(21.3%); and NYHA IV, four patients (2.5%). Causes of 
death during the first month of follow up were: four cardiac 
arrest (two asystole and two electromechanical dissociation), 
two strokes (one hemorrhagic and one ischemic), one lung 
hemorrhage, one cardiac failure, one mesenteric ischemia, 
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one terminal renal failure, four multiple organ failure and 
two sepsis from respiratory origin. Median follow up period 
was 252.24 ± 232.17 days. A total of 28 (17.5 %) patients 
died during follow-up, 17 of them due to cardiac causes. 
The estimated two year overall and cardiac survival rates 
using the Kaplan-Meier method were 71% and 86.4%, re-
spectively.   
Cox proportional hazard regression showed that the co-
variate EuroSCORE ≥ 20% was the only risk factor related 
to overall mortality (HR: 1.54; 95% CI: 1.22−2.63; P = 
0.042). Cox regression survival curves stratified by this co-
variate are shown in Figure 1. 
Table 3.  Follow-up data (n = 160). 
Duration of hospitalization stay, day 10.42 ± 6.73 
New implantation of a definitive pacemaker 44 (27.5) 
AMI during hospitalization stay 4 (2.5) 
Stroke during hospitalization stay 6 (3.8) 
Mortality during hospitalization stay 14 (8.8) 
Mortality at one month 16 (10) 
Cardiac mortality at one month 14 (8.8) 
Total follow up, day 252.24 ± 232.17
Total mortality at the end of follow-up 28 (17.5) 
Cardiac mortality at the end of follow-up 17 (10.6) 
Data are presented as mean ± SD or n (%). AMI: acute myocardial infarc-
tion. 
 
 
Figure 1.  Cox regression survival curves stratified by the 
covariate EuroSCORE. EuroSCORE: European System for Car-
diac Operative Risk Evaluation. 
4  Discussion 
The main finding of our study is that very elderly patients, 
85 years old and older, with severe and limitative AS show 
good progression after TAVI. 
Although most studies evaluating treatment with TAVI 
usually include elderly people, this certain group has not 
been specifically evaluated in a multicenter and prospective 
manner, as we did in our study. In our cohort of very elderly 
patients, hospital mortality rates are less frequent to those 
predicted by applying the logistic EuroSCORE, and com-
parable with results published in younger patients. We have 
found an overall survival rate comparable to recent previous 
published results.[20−23] 
However, we need to keep in mind that a majority of 
previous studies showed that the EuroSCORE predictive 
model could over-estimate the mortality risk of elderly pa-
tients with AS.[7, 8] 
In very elderly people, association of ageing with other 
co-morbidities may increment significantly the operative 
risk. Concomitantly, an important point is that ageing itself 
may contraindicate surgery without a prohibitive preopera-
tive score. There are many elderly people affected with se-
vere and limitative AS without other co-morbidities, who do 
not undergo surgical replacement because of the prohibitive 
risk associated with their age. Our data showed a mean Eu-
roSCORE of 18.8%. This is not higher than reported in 
other series. Data from other multicenter registries, not spe-
cially designed to evaluate very elderly people, showed 
similar rates of mean logistic EuroSCORE, despite the older 
characteristics of our patients.[20−24] Moreover, we found a 
high proportion of patients with EuroSCORE ≥ 20% 
(64.4%). 
Nevertheless, our data show the main risk factor related 
to overall mortality is a EuroSCORE higher than 20%.  
Similar results were found in an aged-stratified sub- 
analysis of the German Registry, where the authors reported 
a higher rate of co-morbidities in younger patients.[24] 
A high success procedural rate was achieved, according to 
those obtained in several registries with younger population. 
The mean length of hospital stay was 10 days, which is 
quite longer than reported in multicenter registries, but it 
had no influence on both the 30-day or long term mortal-
ity.[20−24] 
Regarding pacemaker implantation, our rate was similar 
to that reported in one recent series with the same device, 
and lower than shown in older series.[25,26] 
Cumulative 30-day mortality was 10%, which is compa-
rable with previous published data about TAVI and also 
with 30-day mortality recently reported in aortic replace-
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ment in elderly patients (≥ 80 years old). Overall survival 
was similar to reported data unclassified by age from other 
multicenter studies.[20, 23−30] 
Havakuk et al.[31] have recently reported that patients of 
age over 85 years do not necessarily predict higher rates of 
complications and 30 days mortality. 
Ageing is an important prognostic factor and obviously it 
should be taken into account, but age itself should not pre-
clude the possibility of undergoing TAVI. Related to this, it 
has been recently suggested that geriatricians should be part 
of the Heart Team in order to complete a global assessment 
of this frail group of patients.[32] 
There are also increasingly interesting novel scenarios 
and co-existing contingencies in elderly AS patients where 
TAVI has also shown its efficacy: porcelain aorta, left ven-
tricular dysfunction and degenerative biological prosthe-
sis.[33−37] 
In conclusion, our study proposes that TAVI is safe and 
effective in a selected population of very elderly patients. 
Our findings support that this new procedure can be consid-
ered as an alternative treatment to AS in this complex group 
of patients. 
Some limitations should be acknowledged. First, we in-
cluded a relatively small sample size; however, to recruit 
cohorts that are to undergo TAVI from this population of 
very elderly patients is difficult. This study includes real 
world data from three high volume TAVI hospitals. Second, 
follow-up is limited to two years. These two limitations did 
not allow us to identify other factors related to mortality. 
Third, we did not perform a cost analysis.  
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